Source comparison
BPC-157 vs TB-4: Research Application Comparison
Tendon/Ligament Repair Accelerates collagen synthesis by 60% at 14 days; increases tensile strength in transection models Moderate improvement in late-phase remodeling; less effective in early structural repair BPC-157 primary; add TB-4 weeks 3–6 for vascular
This comparison does not assign a generated winner or score.
- Tendon/Ligament Repair
- Accelerates collagen synthesis by 60% at 14 days; increases tensile strength in transection models
- Moderate improvement in late-phase remodeling; less effective in early structural repair
- BPC-157 primary; add TB-4 weeks 3–6 for vascular integration
- BPC-157 is the lead compound for acute structural repair
- Cardiac Tissue Recovery
- Limited direct cardiac benefit; indirect support via systemic angiogenesis
- Reduces infarct size 30–40%; improves ejection fraction 12% at 4 weeks post-MI
- TB-4 primary; BPC-157 adjunctive only if systemic healing needed
- TB-4 is the clear choice for myocardial regeneration
- Wound Healing (Non-Diabetic)
- Accelerates epithelialization; effective in mucosal and dermal wounds
- Enhances keratinocyte migration; reduces scar formation through collagen remodeling
- Either compound effective; choose based on phase. BPC-157 acute, TB-4 remodeling
- Both perform well; timing determines optimal selection
- Wound Healing (Diabetic Models)
- Modest improvement; limited efficacy in impaired angiogenesis contexts
- Restores angiogenesis in diabetic wounds; superior outcomes vs untreated controls
- TB-4 primary; BPC-157 secondary or omitted
- TB-4 overcomes diabetic angiogenic impairment more effectively
- Inflammation Resolution
- Mild anti-inflammatory effect; primarily accelerates healing to reduce inflammation duration
- Direct macrophage polarization (M1→M2); reduces pro-inflammatory cytokine expression
- TB-4 for chronic inflammation; BPC-157 for acute injury with secondary inflammation
- TB-4 directly modulates immune pathways; BPC-157 is indirect
- GI Mucosal Repair
- Proven efficacy in ulcer models; promotes epithelial migration and angiogenesis at ulcer margins
- Limited GI-specific research; no documented advantage over BPC-157 in this context
- BPC-157 is the established choice for gastric or intestinal mucosa repair
- BPC-157 has the evidence base for GI applications